Searched for
CUSTOM SYNTHESIS BUSINESS
Holding stocks is harder than finding them: 10 mid- and small-caps stocks that may be worth holding on toHolding a stock is not an act of blind faith. It is not refusing to change one’s mind. It is not averaging down because the stock has falle...- Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...
- Cohance Lifesciences shares rocket 43% in just 2 trading sessions. Here’s what is fuelling the surgeCohance Lifesciences shares surged over 43% in two days following the appointment of former Cipla CEO Umang Vohra as Executive Chairman and...
- Cohance Lifesciences shares skyrocket 20% on hiring former Cipla CEO Umang VohraShares of Cohance Lifesciences surged 20% on Monday after the appointment of former Cipla CEO Umang Vohra as its new Executive Chairman and...
- Divi's Labs Q3 net profit zooms 66% to Rs 594 croreDivi's Laboratories on Monday reported a 66% year-on-year (YoY) jump in net profit to Rs 594 crore for the quarter ended December 31, 2024 ...
- Divi’s Laboratories Q2 Results: Company posts 47% jump in net profit in Q2FY25Divi's Laboratories witnessed a 46.6% surge in profit, reaching Rs. 510 crores in Q2FY25, fueled by robust growth in their custom synthesis...
- JetSynthesys signs pact with Japan’s Digital Hearts HoldingsAs part of this collaboration, the company said DHH will invest in JetSynthesys Japan while JetSynthesys Japan will harness DHH's expertise...
- Pharma can give PI Industries the growth booster it needsDespite hindrances, the stock has delivered a tremendous CAGR of 43, 25 and 37 per cent in 3, 5 and 10 years, respectively. This makes PI a...
- First up: Jefferies puts buy rating on Gland, Laurus LabsJefferies has initiated coverage on Gland Pharma and Laurus Labs with buy ratings as it believes that Indian contract development and manuf...
- Up 670% in 4 years, this API maker’s adrenaline rush is simply not endingThe stock escaped the broader selloff of March 2020 and remained unfazed in the face of the Covid 2.0 volatility, as it kept on hitting rec...
- Buy Laurus Labs, target Rs 480: HDFC SecuritiesBuy Laurus Labs at a price target of Rs 480.
- Buy Divi's Laboratories, target Rs 1,600: Axis CapitalBuy Divi's Laboratories Ltd. at a price target of Rs 1600.
- Our strategy is to file 8-10 ANDAs per year: Laurus Labs founder“Shorter regulatory approval timelines mean there is a scope for new players and integrated players like us”
- Citi initiates coverage on PI Industries with ‘buy’Citi said the strong order book of $850 million of PI Industries’ custom synthesis and manufacturing business adds a clear revenue visibili...
- Expect 18-20% growth for PI in next one year: Mayank Singhal, MD & CEO"As a business as we are achieving scale and height. Growth numbers are definitely going to continue to shore up, but we believe in setting...
- Agrochem industry expected to double in next five years: Mayank Singhal, PI IndustriesThe Indian agrochem industry is expected to be between $2 billion and $2.5 billion, and is expected to double in the next five years.
- PI Industries aims to double turnover to Rs 1,750 cr by FY 15In the agro-chemicals market, which is worth Rs 12,000 to 13,000 crore, PI Industries in among the top five players.
- Looking for a 50% increase in PAT: Salil Singhal, chairman, PI IndustriesIn an interview with ET Now, Salil Singhal, chairman, PI Industries, talks about their quarterly performance and margin outlook.
- Shasun to project R&D identityChennai-based Shasun Chemicals and Drugs is aiming to change its image as a bulk drug manufacturer to one of a research-driven company in t...
- Shasun to project R&D identityThe Chennai-based Shasun Chemicals and Drugs is aiming to change its image as a bulk drug manufacturer to one of a research-driven company ...
Load More
